 "Core Diagnostics to collaborate with US-based Star Health for oncology test")
Core Diagnostics, the clinical diagnostics laboratory, will collaborate with Star Health Network Inc, a New York-based healthcare company, to bring the Celsee Diagnostics’ liquid biopsy test in India. Core Diagnostics will add the CTC (circulating tumour cells) test to its expanding list of tests, and market the product to the patient population across India.
Technology of Celsee Diagnostics, a privately held Michigan-based company that has developed automated systems to detect CTCs from blood, allows healthcare professionals to determine prognosis of cancer patients and efficacy of drug treatment.
Primary and metastatic tumours shed cells into the bloodstream. These are called circulating tumour cells. The Celsee CTC test detects cancer cells in the blood stream and determines whether cancer treatment is working, or the disease is spreading. The test is a valuable aid to oncologists in evaluating prognosis of metastatic breast, colorectal, prostate and lung cancers.
“We are happy to partner with Star Health Network, and to add this state-of-the-art CTC test to our growing menu. Oncology is a rapidly developing field with a focus on research and early detection. We sincerely hope that this diagnostic test will help oncologists plan the best possible targeted treatments, for the most successful patient outcomes,” said Zoya Brar, founder & managing director, Core Diagnostics.
Dr Jamal Naiyer, CEO of Star Health Network, added, “CTC is an instrumental technology in aiding cancer treatment. Star Health Network is helping commercialise Celsee CTC technology across India and is excited to forge the collaboration with Core Diagnostics.”
Core Diagnostics Pvt Ltd is a clinical diagnostic laboratory specialising in high-end esoteric tests in the spheres of oncology, reproductive health, cardiology, and endocrinology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%